HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAsafety guidance84% confidence

FDA Alerts Health Care Providers to Cases of Neurologic Complications from General Anesthesia Linked to Genetic Variant in Patients of Maternal Venezuelan Ancestry

Source: FDA

Why This Matters

Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Medline; the same agency is already in play for this signal, so precedent weight is higher.

Regulatory Analysis

Food and Drug Administration (FDA) is investigating the safety of sevoflurane and other general anesthetics based on published scientific reports of unexpected catastrophic outcomes, including severe neurologic adverse outcomes and death, occurring in adult and pediatric patients.

Supporting Context

Therapeutic area
Infection Control · Medical Devices
Sub-indication
General

Related signal: FDA Alerts on Non-Sterile BD ChloraPrep Applicators in Medline Convenience Kits

Source

View source document

Related Signal

Open signal — FDA Alerts on Non-Sterile BD ChloraPrep Applicators in Medline Convenience Kits
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.